A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)

Trial ID or NCT#

NCT01377922

Status

not recruiting iconNOT RECRUITING

Purpose

A Phase 3 study to evaluate the efficacy and safety of Amifampridine Phosphate in patients with Lambert-Eaton Myasthenic Syndrome (LEMS).

Official Title

A Phase 3, Double-blind, Placebo-controlled, Randomized Discontinuation Study Followed by Open-label Extension Evaluating Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Sarada Sakamuri, MD
Sarada Sakamuri, MD
Neuromuscular neurologist, General neurologist, Neurophysiologist, Neurologist
Clinical Associate Professor, Adult Neurology Clinical Associate Professor (By courtesy), Neurosurgery

View on ClinicalTrials.gov